Advancing precision health through whole genome insights
What we do
Inocras is on a mission to transform how the world diagnoses and treats genetic diseases.
With a specialization in cancer and rare diseases, our whole genome bioinformatics platform derives actionable insights from a person’s genes by analyzing their unique genomic makeup.
At the forefront of whole-genome technology, our advanced diagnostics platform offers personalized insights tailored to each individual, putting precision health within everyone’s reach.
Why whole genome?
Standard panel testing looks at less than 0.1% of your genome1. Similarly, whole exome sequencing analyzes 1-2%2, leaving plenty of room for unanswered questions. Recent studies revealed that complicated mutations are often not captured in standard panel testing and whole exome sequencing. Our whole genome sequencing test offers enhanced clarity by offering a broader and more detailed view and analysis of your genetic makeup.
> 25%
of cancer patients have complicated mutations
(structural variants and/or identified variants in non-coding regions) that are often missed in standard panel DNA sequencing, whole exome sequencing3, and other DNA tests.
Who we serve
What we provide
We see more than 99% of your genetic makeup.
Our whole genome sequencing data offers a broader and more detailed analysis of your genetic makeup. This gives enhanced clarity when it comes to your health.
We help you understand the data so you can make informed decisions.
Our proprietary bioinformatics platform is designed to thoroughly analyze all of your genomic data and translate it into meaningful findings. Our user-friendly personalized reports empower you to confidently navigate your genetic data, assisting you in making informed decisions throughout your journey.
We support you with services that help you take action.
Our mission does not end simply at providing insights. We are here for you — patients, physicians, and researchers — helping you to fully understand your DNA test results with our in-house clinicians and medical experts. We also connect patients to matching clinical trials.
Our products
Whether you’re seeking additional insights for cancer treatment options or navigating a diagnostic journey for a rare disease, our genomic tests provide valuable information to aid your next steps.
CancerVision
Supports you to explore a wider range of treatment options.
- Cancer profiling solution for solid tumors
- Extensive analysis of the whole genomic makeup of your cancer
- Easy-to-read report with actionable treatment options
- Enhanced opportunities for clinical trial participation for new therapeutics
- Support from a genetic counselor for patients and physicians
RareVision
Shorten the diagnostic odyssey and the time to a genetic diagnosis for rare diseases.
- Identify genes associated with rare diseases from one of the most up-to-date databases*
- Extensive analysis of the whole genomic makeup of your disease
- Genetic counseling support for patients and physicians
*https://www.disgenetplus.com/DbInfo#gdaStatistics
**While all patient names provided are fictionalized to ensure privacy and confidentiality, the age, disease information, and diagnostic process in the testimonials are based on real cases. Please note that clinical outcomes may vary for each individual.
5 myths about whole genome sequencing
Wouldn’t whole genome sequencing (WGS) usually have lower depth reading vs. targeted panel sequencing due to its broader coverage?
Our test utilizes Target-Enhanced WGS, which combines the advantages of targeted panels and WGS. For our CancerVision test, for example, we achieve an average of 500x the depth for over 500 critically important genes, which is comparable to the best-in-class panel sequencing depth, and 40x the depth for the person’s entire genome, providing comprehensive coverage beyond the targeted genes7.
Does whole genome sequencing services give me too much data, making it hard to understand?
Inocras provides an easy-to-understand report using our proprietary algorithm. This algorithm ensures that the report focuses on the most relevant and actionable findings for diagnostic and clinical utility..
Our report highlights actionable findings that have implications for treatment options and other relevant findings related to genomic instability and germline analysis. By focusing on these key areas, our report delivers the clinically critical and relevant information to healthcare providers and patients.
Standard panel sequencing is developed around available treatments. Wouldn’t the clinical WGS insights be less helpful if there is no available treatment?
Our findings cover more than just known genetic variations with treatment options. We also uncover copy number variations, structural alterations, and other genome-wide signatures that help inform clinical decisions. This approach aims to provide comprehensive genetic insights, reducing the need for further tests. Plus, our reports list any relevant clinical trials available today.
Even if treatments or clinical trials aren’t available right now, patients will receive information about mutations that might create opportunities for participation in future clinical trials.
Isn’t genomic testing expensive compared to a panel test?
We provide valuable genomic information at a comparable price to the average standard panel sequencing test.
Doesn't it take longer to receive results than standard panel tests?
We prioritize delivering results promptly and aim for efficiency in our processes. Our current turnaround time is 14 days from receipt of samples on average, aligning with the industry’s best-in-class testing standards.
This ensures patients receive their sequencing results in a timely manner, enabling healthcare providers to make informed decisions about their care. However, please note that the time from ordering the test to receiving results may vary depending on how long it takes for samples to reach our laboratory.
Frequently asked questions
How can I order a test as a patient?
CancerVision and RareVision tests can be ordered online using our secure portal. Once you fill out the order form, a telehealth provider will review your test order request and the test will be ordered after they review your information.
What kind of samples are collected?
CancerVision will require tissue and blood samples while RareVision will require a blood sample. Providers and researchers will receive detailed sample collection requirements in an instruction sheet once the test is ordered.
How are the test results shared?
Comprehensive genetic test results are shared with the provider who ordered the test. The provider will then share the results with the patient.